KBL Merger Corp. IV (KBLM), released details this morning on their previously announced non-binding term sheet ahead of their June 5th extension vote. KBLM’s LOI with with CannBioRx Life Sciences Corp. (“CannBioRx”), would form a company combined of three programs focused on treating inflammatory diseases:
- 180 Therapeutics, a late clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic therapies for treating fibrosis;
- Katexco Pharmaceuticals, a pre-clinical effort for developing orally available therapies harnessing the brain’s nicotinic receptors to treat inflammatory diseases; and
- CannBioRexPharmaceuticals, a pre-clinical initiative focused on the development and commercialization of man-made cannabinoids for arthritis, pain, diabetes and obesity.
Important to note, KBL states these opportunities are non-plant-touching, pharmaceutical-grade, non-psychoactive cannabis and drug development programs.
Shareholder Vote to Extend: To be held June 5th, record date is May 15th
No further details on the transaction have been released as of yet, but it is important to note that KBLM will be changing it’s previous extension amendment. Per the first extension amendment, KBLM had previously agreed to contribute $0.03 for each public share that was not redeemed for each calendar month commencing on June 7, 2019, through September 7, 2019 (should they need the full three months). However, KBLM is now asking for a potential six months, which would move their potential deadline date to December 7th instead. Additionally, instead of $0.03 per share per month, KBLM will now be contributing $0.025 per share per month, for a total of $0.15 per share should they need the full six months.
Quick Takes: While cannabis companies are hot, we still do not have a lot of details on this transaction. However, two out of the three of CannBioRx’s programs are at the pre-clincial stage. It’s difficult to evaluate the opportunity without specifics, but clearly this was announced ahead of the extension vote to give shareholders something to chew on before they decide to redeem or not. However, reducing the per month contribution from $0.03 to $0.025 might be detrimental. A longer duration and a reduced monthly contribution are generally not well received by SPAC investors.
At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...